Navigation Links
StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP)
Date:11/11/2010

COVINA, Calif., Nov. 11, 2010 /PRNewswire/ -- StemCyte, Inc., one of the world's preeminent umbilical cord blood (UCB) banks and biotherapy companies, is proud to announce that the Company has been awarded two cash grants totaling $488,950 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program designed to support biomedical research by firms with fewer than 250 employees.

The Patient Protection and Affordable Care Act of 2010 (PPACA) created the QTDP program as a means to support qualified research and development projects that show significant potential to produce new and cost-saving therapies, support job growth and increase U.S. competitiveness.  Following a competitive application process, StemCyte was awarded two grants for advance therapies using UCB stem cells for the potential treatment of chronic spinal cord injury and chronic stroke.

"We are very pleased to have been awarded these grants and believe it reflects positively on the Advanced Therapeutic applications of cord blood stem cells that we continue to pursue," said Ken Giacin, StemCyte, Inc's Chairman and CEO.  "These awards reaffirm our belief that our UCB-related research has great potential for saving and improving lives."

The Internal Revenue Service issued the QTDP awards and will administer the program.  The QTDP program is designed to provide grants and tax credits to qualified biotechnology companies with fewer than 250 employees that demonstrate the potential to develop new therapies to treat chronic condition, address unmet medical needs, reduce health care costs, and advance the goal of curing cancer within 30 years.

About StemCyte, Inc.

Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world.  StemCyte has supplied over 1,300 cord blood products for over 40 life-threatening diseases to over 200 leading worldwide transplant centers.  StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies.  They are supporting the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, as well as supporting trials investigating regenerative spinal cord therapies.  They are the only for-profit company contracted by the US Department of HHS to establish a public National Cord Blood Inventory for unrelated transplant units.  Its headquarters are located in Covina, Ca. and Ewing, NJ.  To learn more visit www.StemCyte.com.


'/>"/>
SOURCE StemCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 7-Time Olympic Medalist Shannon Miller Endorses StemCyte
2. Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer
3. U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
4. Catapult Systems Awarded SharePoint 2010 and FAST Intranet Project
5. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
6. Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project
7. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
8. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
9. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
10. Federal nanotechnology renewal grant awarded to ASU faculty
11. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... to the scientific and clinical research community’s growing body of knowledge during its ... in the Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, ...
(Date:4/20/2017)... , ... April 20, 2017 , ... Parallel6™ , ... trials worldwide, announced today that they were named one of the 2017 Top ... the latest developments in the pharmaceutical industry. , “We take pride in honoring Parallel6 ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... 2017 , ... Optofluidics today announced that it's changing its ... changed focus to making analytical tools for biopharmaceutical quality control. “We are excited ... Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson have steered the ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):